First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis.

Front Endocrinol (Lausanne) · 2024 · PMC10860745 · PMID 38348420

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

However, our study did find a borderline significant association between SGLT2i use and an increased risk of urinary tract infection (OR: 2.31, 95% CI: 1.00, 5.34).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.